Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 674
REVIEW ARTICLE
Year : 2014  |  Volume : 6  |  Issue : 3  |  Page : 107-113

Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus


1 Quantum Solutions India, DLF building, Chandigarh Technology Park, Chandigarh, India
2 Department of Pharmacology, AIIMS, New Delhi, India
3 Central Leprosy Teaching and Research Institute, Chengalpattu, Tamilnadu, India
4 Department of Pharmacology, Govt. Medical College Patiala, Punjab, India

Correspondence Address:
Harmanjit Singh
Department of Pharmacology, AIIMS, New Delhi
India
Login to access the Email id

Source of Support: This article received no specifi c grant from any funding agency in the public, commercial, or not for-profi t sectors., Conflict of Interest: None


DOI: 10.4103/1947-2714.128471

Rights and Permissions

Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs having an insulin-independent mechanism that offers a considerable advantage of increasing urinary glucose excretion without inducing hypoglycemia and promoting weight loss due to loss of 300 to 400kcal/day, Canagliflozin being the 1 st successful candidate of this group and became the first SGLT2 inhibitor to be FDA approved on March 29, 2013. In various clinical trials, it has shown promising results in controlling glycemia, causing weight loss, reducing systolic and diastolic BP and cardiovascular risk. There are some safety concerns associated with its use e.g. genital mycotic infections, increased urination, urinary tract infection and hyperkalemia, which need to be carefully addressed while using this drug.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4074    
    Printed62    
    Emailed2    
    PDF Downloaded1251    
    Comments [Add]    
    Cited by others 9    

Recommend this journal